Connect with us

Business

ENDEXX CORPORATION COM (OTCMKTS:EDXC) Announces Plans for Clinical Study on CBD Capsules for Neuropathic Pains

Published

on

ENDEXX CORPORATION COM (OTCMKTS:EDXC) has announced that it would be conducting an adaptive clinical study, under the supervision of a doctor, for its proprietary CBD capsules. The study would determine the efficacy of the capsules in patients with neuropathic pains. The company plans to enroll a total of 20 patients, in 4 separate groups, supervised by 4 different doctors.

ENDEXX has chosen Dr. Martin Pressman for the site at New Haven in Connecticut, Dr. Daniel Kiddy and Dr. Michael Horwitz, at St. Louis, Missouri and Dr. Daniel Brandwein at Weston, Florida. The capsules make use of cannabidiol as the primary ingredient and come as a dual pack, for day and night dosage. The doctors would be monitoring the progress of the patients, who would be administered the capsules twice a day. The findings would later be sent for review, by an independent review board.

The CEO of ENDEXX, Todd Davis, updated the shareholders of the company on the matter, stating that EDXC had identified two pathways, for its CBD initiative. They included the market for therapeutic and nutraceutical drugs and the market for wellness and nutrition. He clarified that this study is a part of the therapeutics market, where the company has worked with certified pharmacists, in a medical environment, for the formulation of CBD infused products. As a result ENDEXX has been able to come up with safe products, with effective delivery methods.

The CEO also went on to state that, in the wellness market, the company had identified the demographic age of 40+, which demands prolonged wellness and an improved quality of life. Current Phyto-Cannabinoids-Rich products, from ENDEXX, have been known to improve the overall quality of the patient’s life. The study is also an extension of the works previously done by Dr. Kiddy and Dr. Brandwein.

ENDEXX CORPORATION COM (OTCMKTS:EDXC) completed the April 25 trading session, with a loss of 17.44% to its share value, after having a trade volume of 552,681, to reach a close at $0.0232 per share.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of MMJReporter.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement